Cardiovascular Systems, Inc. (NASDAQ: CSII) Stock Competitors & Peer Comparison

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, ABT has a market cap of 186.5B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while ABT trades at $107.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas ABT's P/E ratio is 20.69. In terms of profitability, CSII's ROE is -0.14%, compared to ABT's ROE of +0.11%. Regarding short-term risk, CSII is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for CSII.Check ABT's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, CSII's ROE is -0.14%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, CSII is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for CSII.Check BSX-PA's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, SYK has a market cap of 130B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while SYK trades at $339.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas SYK's P/E ratio is 25.32. In terms of profitability, CSII's ROE is -0.14%, compared to SYK's ROE of +0.16%. Regarding short-term risk, CSII is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for CSII.Check SYK's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, MDT has a market cap of 111.6B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while MDT trades at $87.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas MDT's P/E ratio is 15.76. In terms of profitability, CSII's ROE is -0.14%, compared to MDT's ROE of +0.10%. Regarding short-term risk, CSII is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for CSII.Check MDT's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, BSX has a market cap of 73.3B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while BSX trades at $49.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas BSX's P/E ratio is 15.91. In terms of profitability, CSII's ROE is -0.14%, compared to BSX's ROE of +0.15%. Regarding short-term risk, CSII is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for CSII.Check BSX's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, EW has a market cap of 51.7B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while EW trades at $89.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas EW's P/E ratio is 33.23. In terms of profitability, CSII's ROE is -0.14%, compared to EW's ROE of +0.10%. Regarding short-term risk, CSII is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for CSII.Check EW's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, DXCM has a market cap of 32B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while DXCM trades at $84.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas DXCM's P/E ratio is 36.37. In terms of profitability, CSII's ROE is -0.14%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, CSII is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for CSII.Check DXCM's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, RMD has a market cap of 30.7B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while RMD trades at $211.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas RMD's P/E ratio is 19.68. In terms of profitability, CSII's ROE is -0.14%, compared to RMD's ROE of +0.24%. Regarding short-term risk, CSII is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for CSII.Check RMD's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, PHG has a market cap of 26.1B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while PHG trades at $26.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas PHG's P/E ratio is 15.28. In terms of profitability, CSII's ROE is -0.14%, compared to PHG's ROE of +0.10%. Regarding short-term risk, CSII is less volatile compared to PHG. This indicates lower risk in terms of short-term price fluctuations for CSII.Check PHG's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, ZBH has a market cap of 18.7B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while ZBH trades at $96.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas ZBH's P/E ratio is 11.38. In terms of profitability, CSII's ROE is -0.14%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, CSII is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for CSII.Check ZBH's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas ABMD's P/E ratio is 65.36. In terms of profitability, CSII's ROE is -0.14%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, CSII is less volatile compared to ABMD. This indicates lower risk in terms of short-term price fluctuations for CSII.Check ABMD's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while PEN trades at $324.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas PEN's P/E ratio is 84.77. In terms of profitability, CSII's ROE is -0.14%, compared to PEN's ROE of +0.11%. Regarding short-term risk, CSII is less volatile compared to PEN. This indicates lower risk in terms of short-term price fluctuations for CSII.Check PEN's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, SNN has a market cap of 12.6B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while SNN trades at $30.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas SNN's P/E ratio is 14.16. In terms of profitability, CSII's ROE is -0.14%, compared to SNN's ROE of +0.12%. Regarding short-term risk, CSII is less volatile compared to SNN. This indicates lower risk in terms of short-term price fluctuations for CSII.Check SNN's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas SWAV's P/E ratio is 78.76. In terms of profitability, CSII's ROE is -0.14%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, CSII is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for CSII.Check SWAV's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while ALGN trades at $173.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas ALGN's P/E ratio is 15.83. In terms of profitability, CSII's ROE is -0.14%, compared to ALGN's ROE of +0.14%. Regarding short-term risk, CSII is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for CSII.Check ALGN's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, GMED has a market cap of 11.1B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while GMED trades at $82.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas GMED's P/E ratio is 18.56. In terms of profitability, CSII's ROE is -0.14%, compared to GMED's ROE of +0.12%. Regarding short-term risk, CSII is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for CSII.Check GMED's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, GKOS has a market cap of 10.6B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while GKOS trades at $180.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas GKOS's P/E ratio is -209.45. In terms of profitability, CSII's ROE is -0.14%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, CSII is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for CSII.Check GKOS's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, PODD has a market cap of 9.8B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while PODD trades at $141.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas PODD's P/E ratio is 24.05. In terms of profitability, CSII's ROE is -0.14%, compared to PODD's ROE of +0.27%. Regarding short-term risk, CSII is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for CSII.Check PODD's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, BIO-B has a market cap of 9.5B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while BIO-B trades at $349.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas BIO-B's P/E ratio is 103.54. In terms of profitability, CSII's ROE is -0.14%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, CSII is less volatile compared to BIO-B. This indicates lower risk in terms of short-term price fluctuations for CSII.Check BIO-B's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, BIO has a market cap of 9.5B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while BIO trades at $352.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas BIO's P/E ratio is 38.00. In terms of profitability, CSII's ROE is -0.14%, compared to BIO's ROE of +0.03%. Regarding short-term risk, CSII is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for CSII.Check BIO's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas MASI's P/E ratio is 44.43. In terms of profitability, CSII's ROE is -0.14%, compared to MASI's ROE of +0.09%. Regarding short-term risk, CSII is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for CSII.Check MASI's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, BRKR has a market cap of 8.1B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while BRKR trades at $53.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas BRKR's P/E ratio is 26.84. In terms of profitability, CSII's ROE is -0.14%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, CSII is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for CSII.Check BRKR's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas NARI's P/E ratio is -59.24. In terms of profitability, CSII's ROE is -0.14%, compared to NARI's ROE of -0.00%. Regarding short-term risk, CSII is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for CSII.Check NARI's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while ITGR trades at $125.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas ITGR's P/E ratio is 19.72. In terms of profitability, CSII's ROE is -0.14%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, CSII is less volatile compared to ITGR. This indicates lower risk in terms of short-term price fluctuations for CSII.Check ITGR's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, IRTC has a market cap of 4.2B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while IRTC trades at $127.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas IRTC's P/E ratio is -199.75. In terms of profitability, CSII's ROE is -0.14%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, CSII is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for CSII.Check IRTC's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while LIVN trades at $76.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas LIVN's P/E ratio is 18.10. In terms of profitability, CSII's ROE is -0.14%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, CSII is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for CSII.Check LIVN's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, HAE has a market cap of 4B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while HAE trades at $87.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas HAE's P/E ratio is 17.54. In terms of profitability, CSII's ROE is -0.14%, compared to HAE's ROE of +0.11%. Regarding short-term risk, CSII is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for CSII.Check HAE's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas AXNX's P/E ratio is -709.80. In terms of profitability, CSII's ROE is -0.14%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, CSII is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for CSII.Check AXNX's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while TMDX trades at $83.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas TMDX's P/E ratio is 42.58. In terms of profitability, CSII's ROE is -0.14%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, CSII is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for CSII.Check TMDX's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, AXGN has a market cap of 2.5B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while AXGN trades at $46.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas AXGN's P/E ratio is 122.18. In terms of profitability, CSII's ROE is -0.14%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, CSII is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for CSII.Check AXGN's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, UFPT has a market cap of 2.4B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while UFPT trades at $314.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas UFPT's P/E ratio is 32.07. In terms of profitability, CSII's ROE is -0.14%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, CSII is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for CSII.Check UFPT's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, BFLY has a market cap of 2.3B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while BFLY trades at $8.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas BFLY's P/E ratio is -36.77. In terms of profitability, CSII's ROE is -0.14%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, CSII is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for CSII.Check BFLY's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, ESTA has a market cap of 2.3B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while ESTA trades at $77.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas ESTA's P/E ratio is -61.44. In terms of profitability, CSII's ROE is -0.14%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, CSII is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for CSII.Check ESTA's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas NUVA's P/E ratio is 75.00. In terms of profitability, CSII's ROE is -0.14%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, CSII is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for CSII.Check NUVA's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while NVCR trades at $16.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas NVCR's P/E ratio is -10.71. In terms of profitability, CSII's ROE is -0.14%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, CSII is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for CSII.Check NVCR's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while INSP trades at $60.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas INSP's P/E ratio is 26.51. In terms of profitability, CSII's ROE is -0.14%, compared to INSP's ROE of +0.18%. Regarding short-term risk, CSII is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for CSII.Check INSP's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, TNDM has a market cap of 1.5B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while TNDM trades at $22.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas TNDM's P/E ratio is -20.35. In terms of profitability, CSII's ROE is -0.14%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, CSII is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for CSII.Check TNDM's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while ENOV trades at $26.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas ENOV's P/E ratio is 7.62. In terms of profitability, CSII's ROE is -0.14%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, CSII is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for CSII.Check ENOV's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while CNMD trades at $49.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas CNMD's P/E ratio is 10.78. In terms of profitability, CSII's ROE is -0.14%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, CSII is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for CSII.Check CNMD's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while ATEC trades at $9.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas ATEC's P/E ratio is -155.17. In terms of profitability, CSII's ROE is -0.14%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, CSII is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for CSII.Check ATEC's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while IART trades at $17.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas IART's P/E ratio is 7.31. In terms of profitability, CSII's ROE is -0.14%, compared to IART's ROE of -0.01%. Regarding short-term risk, CSII is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for CSII.Check IART's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while AORT trades at $27.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas AORT's P/E ratio is 45.28. In terms of profitability, CSII's ROE is -0.14%, compared to AORT's ROE of -0.01%. Regarding short-term risk, CSII is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for CSII.Check AORT's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas HSKA's P/E ratio is -62.49. In terms of profitability, CSII's ROE is -0.14%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, CSII is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for CSII.Check HSKA's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while IRMD trades at $92.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas IRMD's P/E ratio is 46.48. In terms of profitability, CSII's ROE is -0.14%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, CSII is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for CSII.Check IRMD's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas AVNS's P/E ratio is 27.77. In terms of profitability, CSII's ROE is -0.14%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, CSII is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for CSII.Check AVNS's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while PRCT trades at $20.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas PRCT's P/E ratio is -10.52. In terms of profitability, CSII's ROE is -0.14%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, CSII is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for CSII.Check PRCT's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas SILK's P/E ratio is -18.96. In terms of profitability, CSII's ROE is -0.14%, compared to SILK's ROE of -0.35%. Regarding short-term risk, CSII is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for CSII.Check SILK's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while LMRI trades at $11.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas LMRI's P/E ratio is -22.53. In terms of profitability, CSII's ROE is -0.14%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, CSII is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for CSII.Check LMRI's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas FNA's P/E ratio is -19.83. In terms of profitability, CSII's ROE is -0.14%, compared to FNA's ROE of -0.35%. Regarding short-term risk, CSII is less volatile compared to FNA. This indicates lower risk in terms of short-term price fluctuations for CSII.Check FNA's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, BVS has a market cap of 956.9M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while BVS trades at $14.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas BVS's P/E ratio is 18.59. In terms of profitability, CSII's ROE is -0.14%, compared to BVS's ROE of +0.28%. Regarding short-term risk, CSII is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for CSII.Check BVS's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, INMD has a market cap of 880M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while INMD trades at $15.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas INMD's P/E ratio is 10.63. In terms of profitability, CSII's ROE is -0.14%, compared to INMD's ROE of +0.13%. Regarding short-term risk, CSII is less volatile compared to INMD. This indicates lower risk in terms of short-term price fluctuations for CSII.Check INMD's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, AVR has a market cap of 866.3M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while AVR trades at $8.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas AVR's P/E ratio is -4.00. In terms of profitability, CSII's ROE is -0.14%, compared to AVR's ROE of -1.24%. Regarding short-term risk, CSII is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for CSII.Check AVR's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, SIBN has a market cap of 825.3M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while SIBN trades at $18.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas SIBN's P/E ratio is -54.74. In terms of profitability, CSII's ROE is -0.14%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, CSII is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for CSII.Check SIBN's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, AHCO has a market cap of 774.1M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while AHCO trades at $5.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas AHCO's P/E ratio is 11.61. In terms of profitability, CSII's ROE is -0.14%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, CSII is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for CSII.Check AHCO's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, SSII has a market cap of 754.5M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while SSII trades at $3.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas SSII's P/E ratio is -73.53. In terms of profitability, CSII's ROE is -0.14%, compared to SSII's ROE of -0.23%. Regarding short-term risk, CSII is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for CSII.Check SSII's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, BBNX has a market cap of 715.3M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while BBNX trades at $15.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas BBNX's P/E ratio is -10.53. In terms of profitability, CSII's ROE is -0.14%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, CSII is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for CSII.Check BBNX's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, CBLL has a market cap of 713.7M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while CBLL trades at $18.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas CBLL's P/E ratio is -11.54. In terms of profitability, CSII's ROE is -0.14%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, CSII is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for CSII.Check CBLL's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, TCMD has a market cap of 665.4M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while TCMD trades at $29.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas TCMD's P/E ratio is 33.52. In terms of profitability, CSII's ROE is -0.14%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, CSII is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for CSII.Check TCMD's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas SRDX's P/E ratio is -34.66. In terms of profitability, CSII's ROE is -0.14%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, CSII is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for CSII.Check SRDX's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, BWAY has a market cap of 608M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while BWAY trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas BWAY's P/E ratio is 39.38. In terms of profitability, CSII's ROE is -0.14%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, CSII is less volatile compared to BWAY. This indicates lower risk in terms of short-term price fluctuations for CSII.Check BWAY's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, KIDS has a market cap of 584.8M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while KIDS trades at $22.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas KIDS's P/E ratio is -19.30. In terms of profitability, CSII's ROE is -0.14%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, CSII is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for CSII.Check KIDS's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas APEN's P/E ratio is -9.43. In terms of profitability, CSII's ROE is -0.14%, compared to APEN's ROE of -0.85%. Regarding short-term risk, CSII is less volatile compared to APEN. This indicates lower risk in terms of short-term price fluctuations for CSII.Check APEN's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, CTKB has a market cap of 542.4M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while CTKB trades at $4.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas CTKB's P/E ratio is -22.25. In terms of profitability, CSII's ROE is -0.14%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, CSII is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for CSII.Check CTKB's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, CSII's ROE is -0.14%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, CSII is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for CSII.Check ZIMV's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, VREX has a market cap of 522.5M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while VREX trades at $12.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas VREX's P/E ratio is 13.06. In terms of profitability, CSII's ROE is -0.14%, compared to VREX's ROE of -0.18%. Regarding short-term risk, CSII is less volatile compared to VREX. This indicates lower risk in terms of short-term price fluctuations for CSII.Check VREX's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, DCTH has a market cap of 521.6M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while DCTH trades at $15.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas DCTH's P/E ratio is 1511.00. In terms of profitability, CSII's ROE is -0.14%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, CSII is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for CSII.Check DCTH's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, NPCE has a market cap of 505.6M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while NPCE trades at $14.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas NPCE's P/E ratio is -25.57. In terms of profitability, CSII's ROE is -0.14%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, CSII is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for CSII.Check NPCE's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, CERS has a market cap of 473.6M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while CERS trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas CERS's P/E ratio is -46.91. In terms of profitability, CSII's ROE is -0.14%, compared to CERS's ROE of -0.10%. Regarding short-term risk, CSII is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for CSII.Check CERS's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, CLPT has a market cap of 426.2M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while CLPT trades at $14.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas CLPT's P/E ratio is -12.04. In terms of profitability, CSII's ROE is -0.14%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, CSII is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for CSII.Check CLPT's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, OFIX has a market cap of 415.5M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while OFIX trades at $10.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas OFIX's P/E ratio is -13.43. In terms of profitability, CSII's ROE is -0.14%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, CSII is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for CSII.Check OFIX's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, SGHT has a market cap of 406.4M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while SGHT trades at $7.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas SGHT's P/E ratio is -13.34. In terms of profitability, CSII's ROE is -0.14%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, CSII is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for CSII.Check SGHT's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, CARL has a market cap of 375.7M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while CARL trades at $13.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas CARL's P/E ratio is -9.66. In terms of profitability, CSII's ROE is -0.14%, compared to CARL's ROE of -0.38%. Regarding short-term risk, CSII is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for CSII.Check CARL's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, PACB has a market cap of 368.1M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while PACB trades at $1.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas PACB's P/E ratio is -2.89. In terms of profitability, CSII's ROE is -0.14%, compared to PACB's ROE of -49.62%. Regarding short-term risk, CSII is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for CSII.Check PACB's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, CV has a market cap of 354.7M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while CV trades at $7.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas CV's P/E ratio is -2.84. In terms of profitability, CSII's ROE is -0.14%, compared to CV's ROE of +1.27%. Regarding short-term risk, CSII is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for CSII.Check CV's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, PMI has a market cap of 349.2M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while PMI trades at $3.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas PMI's P/E ratio is -2.83. In terms of profitability, CSII's ROE is -0.14%, compared to PMI's ROE of +4.99%. Regarding short-term risk, CSII is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for CSII.Check PMI's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, ELMD has a market cap of 348.5M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while ELMD trades at $42.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas ELMD's P/E ratio is 35.97. In terms of profitability, CSII's ROE is -0.14%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, CSII is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for CSII.Check ELMD's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, CATX has a market cap of 342.1M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while CATX trades at $3.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas CATX's P/E ratio is -2.13. In terms of profitability, CSII's ROE is -0.14%, compared to CATX's ROE of -0.42%. Regarding short-term risk, CSII is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for CSII.Check CATX's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas SMLR's P/E ratio is 3.92. In terms of profitability, CSII's ROE is -0.14%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, CSII is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for CSII.Check SMLR's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, TMCI has a market cap of 308.8M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while TMCI trades at $4.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas TMCI's P/E ratio is -5.06. In terms of profitability, CSII's ROE is -0.14%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, CSII is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for CSII.Check TMCI's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, SENS has a market cap of 293.4M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while SENS trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas SENS's P/E ratio is -3.51. In terms of profitability, CSII's ROE is -0.14%, compared to SENS's ROE of -1.66%. Regarding short-term risk, CSII is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for CSII.Check SENS's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, ANIK has a market cap of 286.7M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while ANIK trades at $21.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas ANIK's P/E ratio is 43.71. In terms of profitability, CSII's ROE is -0.14%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, CSII is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for CSII.Check ANIK's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, PROF has a market cap of 269.3M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while PROF trades at $7.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas PROF's P/E ratio is -5.98. In terms of profitability, CSII's ROE is -0.14%, compared to PROF's ROE of -0.56%. Regarding short-term risk, CSII is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for CSII.Check PROF's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, RXST has a market cap of 259.1M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while RXST trades at $6.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas RXST's P/E ratio is -6.73. In terms of profitability, CSII's ROE is -0.14%, compared to RXST's ROE of -0.17%. Regarding short-term risk, CSII is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for CSII.Check RXST's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas MGRM's P/E ratio is -12.00. In terms of profitability, CSII's ROE is -0.14%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, CSII is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for CSII.Check MGRM's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, FOCL has a market cap of 233.1M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while FOCL trades at $6.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas FOCL's P/E ratio is -8.00. In terms of profitability, CSII's ROE is -0.14%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, CSII is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for CSII.Check FOCL's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas NVRO's P/E ratio is -1.91. In terms of profitability, CSII's ROE is -0.14%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, CSII is less volatile compared to NVRO. This indicates lower risk in terms of short-term price fluctuations for CSII.Check NVRO's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, TLSI has a market cap of 212.7M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while TLSI trades at $5.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas TLSI's P/E ratio is -3.34. In terms of profitability, CSII's ROE is -0.14%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, CSII is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for CSII.Check TLSI's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, RCEL has a market cap of 193M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while RCEL trades at $7.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas RCEL's P/E ratio is -4.95. In terms of profitability, CSII's ROE is -0.14%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, CSII is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for CSII.Check RCEL's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas BSGM's P/E ratio is -5.81. In terms of profitability, CSII's ROE is -0.14%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, CSII is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for CSII.Check BSGM's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, QTRX has a market cap of 189.8M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while QTRX trades at $4.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas QTRX's P/E ratio is -2.52. In terms of profitability, CSII's ROE is -0.14%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, CSII is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for CSII.Check QTRX's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas MDGS's P/E ratio is -0.27. In terms of profitability, CSII's ROE is -0.14%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, CSII is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for CSII.Check MDGS's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, STIM has a market cap of 165.6M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while STIM trades at $2.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas STIM's P/E ratio is -4.41. In terms of profitability, CSII's ROE is -0.14%, compared to STIM's ROE of -1.65%. Regarding short-term risk, CSII is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for CSII.Check STIM's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, INGN has a market cap of 163.8M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while INGN trades at $6.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas INGN's P/E ratio is -6.65. In terms of profitability, CSII's ROE is -0.14%, compared to INGN's ROE of -0.13%. Regarding short-term risk, CSII is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for CSII.Check INGN's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas QIPT's P/E ratio is -15.87. In terms of profitability, CSII's ROE is -0.14%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, CSII is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for CSII.Check QIPT's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas ICAD's P/E ratio is -20.37. In terms of profitability, CSII's ROE is -0.14%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, CSII is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for CSII.Check ICAD's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, OWLT has a market cap of 99.9M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while OWLT trades at $5.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas OWLT's P/E ratio is -39.43. In terms of profitability, CSII's ROE is -0.14%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, CSII is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for CSII.Check OWLT's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, LUCD has a market cap of 98.9M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while LUCD trades at $0.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas LUCD's P/E ratio is -2.61. In terms of profitability, CSII's ROE is -0.14%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, CSII is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for CSII.Check LUCD's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, HSDT has a market cap of 98.7M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while HSDT trades at $1.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas HSDT's P/E ratio is -0.02. In terms of profitability, CSII's ROE is -0.14%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, CSII is less volatile compared to HSDT. This indicates lower risk in terms of short-term price fluctuations for CSII.Check HSDT's competition here

Cardiovascular Systems, Inc. (NASDAQ: CSII) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CSII stands at 844M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, CSII is priced at $20.00 on the NASDAQ, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CSII currently has a P/E ratio of -20.83, whereas HJLI's P/E ratio is N/A. In terms of profitability, CSII's ROE is -0.14%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, CSII is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for CSII.Check HJLI's competition here